DarusentanDarusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension. Read from the Drugbox of the Wikipedia article Darusentan, revision 1330795221.

Property

Value

Formula

C22H22N2O6, 410.42 g/mol

Elimination half-life

12.5 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.